Identification of new therapy for HCC based on stemness surface markers
| Project/Area Number |
15K08992
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
OISHI NAOKI 金沢大学, 医学系, 協力研究員 (20507040)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 肝細胞癌 / 上皮間葉系移行 / ヒストン修飾タンパク阻害薬 / DNAメチル化制御タンパク阻害薬 / 癌幹細胞 / HDAC阻害剤 / DNMT阻害剤 / EpCAM / CD133 / CD56 |
|---|
| Outline of Final Research Achievements |
I evaluated the relationship between epithelium-Mesenchymal transition and features of hepatic cancer stem cells. Moreover, I identified new therapy based on a pattern of stemness surface markers. In epithelial-like HCC cases, highly expression of EpCAM or CD133, or activation of HDAC1 pathway indicated poor prognosis. While, in mesenchymal-like HCC cases, highly expression of CD56 or CD90, or activation of DNMT1 or DNMT3b pathways were poor prognostic marker. HDAC1 inhibitor suppressed tumor proliferation and invasion in Epithelial-like HCC cells. On the other hand, DNMT inhibitor showed the anti-tumor effect in Mesenchymal-like HCC cells. In Epithelial-like HCC cells, combination DNA-effected anti-cancer drugs and HDAC inhibitor indicated synergistic effect in the suppression of tumor proliferation and invasion. This combination therapy may be new therapy for Epithelial-like HCC cases.
|
Report
(4 results)
Research Products
(8 results)
-
-
[Journal Article] Sorafenib suppresses extrahepatic metastasis de novo in hepatocellular carcinoma through inhibition of mesenchymal cancer stem cells characterized by the expression of CD90.2017
Author(s)
5.Yoshida M, Yamashita T, Okada H, Oishi N, Nio K, Hayashi T, Nomura Y, Hayashi T, Asahina Y, Ohwada M, Sunagozaka H, Takatori H, Colombo F, Porretti L, Honda M, Kaneko S.
-
Journal Title
Scientific Reports.
Volume: 12;7(1)
Issue: 1
Pages: 11292-11292
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
[Journal Article] Defeating EpCAM(+) liver cancer stem cells by targeting chromatin remodeling enzyme CHD4 in human hepatocellular carcinoma.2015
Author(s)
Nio K, Yamashita T, Okada H, Kondo M, Hayashi T, Hara Y, Nomura Y, Zeng SS, Yoshida M, Hayashi T, Sunagozaka H, Oishi N, Honda M, Kaneko S
-
Journal Title
J. Hepatology
Volume: 5
Issue: 5
Pages: 1164-72
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
[Journal Article] TSU-68 ameliorates hepatocellular carcinoma growth by inhibiting microenvironmental platelet-derived growth factor signaling.2015
Author(s)
Hara Y, Yamashita T, Oishi N, Nio K, Hayashi T, Nomura Y, Yoshida M, Hayashi T, Hashiba T, Asahina Y, Kondo M, Okada H, Sunagozaka H, Honda M, Kaneko S
-
Journal Title
Anticancer R.
Volume: 3
Pages: 1423-31
Related Report
Peer Reviewed / Open Access
-
-
-
-
